AstraZeneca said it entered into a strategic research collaboration with China’s CSPC Pharmaceuticals, focused on artificial intelligence-driven research, valued at up to $5.33 billion.

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the Cardiac Amyloid Reaching for Extended Survival (CARES) ...

CSPC received an upfront payment of $100 million from AstraZeneca and is also eligible to receive up to $1.92 billion for further development and commercialization milestones, plus tiered royalties.

China is being viewed by the biotech and life sciences industry as a threat to US innovation. One pharma CEO thinks it may ...

AstraZeneca (LSE:AZN) recently announced that its investigational antibody, anselamimab, did not achieve statistical ...

AstraZeneca teams up with CSPC in a $1.92 billion deal to develop YS2302018, a novel Lp(a) disruptor aimed at treating cardiovascular disease. Airsupra, AstraZeneca's asthma drug, shows promise in ...

On June 13, AstraZeneca PLC (NASDAQ:AZN) announced that it had entered into a strategic research collaboration with CSPC Pharmaceuticals Group Limited, based in Shijiazhuang City.

AstraZeneca said it would have access to CSPC's pre-clinical candidate small molecule - YS2302018 - an oral Lp(a) disruptor, with the aim to develop it as a lipid-lowerin.

AstraZeneca (NASDAQ:AZN) is looking to boost its cardiovascular pipeline through an exclusive license agreement with CSPC Pharmaceutical Group (CSPC).As part of the deal, AstraZeneca will pay ...

CSPC said the compound was discovered by the Group's AI-driven small molecule drug design platform. AstraZeneca's London-listed shares slipped 0.2% on Monday but have gained 11% this year.